

HOUSE COMMITTEE OF REFERENCE REPORT

Chairman of Committee

Date

April 11, 2017

Committee on Health, Insurance, & Environment.

After consideration on the merits, the Committee recommends the following:

SB17-203 be amended as follows, and as so amended, be referred to the Committee of the Whole with favorable recommendation:

1 Amend reengrossed bill, page 3, line 1, after "DISCONTINUED" insert "BY
2 THE PRESCRIBING HEALTH CARE PROVIDER".

3 Page 3, after line 5 insert:

4 "(3) A CARRIER THAT REQUIRES STEP THERAPY SHALL PROVIDE AN
5 OVERRIDE PROCESS FOR A PRESCRIBED PRESCRIPTION DRUG. A CARRIER
6 MUST EXPEDITIOUSLY GRANT AN OVERRIDE WHEN THE TREATING HEALTH
7 CARE PROVIDER CAN SHOW THAT THE CARRIER'S PREFERRED DRUG IS
8 CONTRAINDICATED OR WILL LIKELY CAUSE AN ADVERSE REACTION. THE
9 TREATING HEALTH CARE PROVIDER MAY USE PEER-REVIEWED DATA OR
10 CLINICAL GUIDELINES OR CLINICAL TRIAL RESULTS AS A PART OF THIS
11 PROCESS."

12 Page 3, line 6, strike "(3)" and substitute "(4)".

13 Page 3, after line 8 insert:

14 "(5) THIS SECTION IS SUBJECT TO THE INTERNAL AND EXTERNAL
15 APPEALS PROCESSES IN SECTIONS 10-16-113 AND 10-16-113.5."

16 Page 3, line 9, strike "(4)" and substitute "(6)".

17 Page 3, strike line 12 and substitute "INSURANCE OR HEALTH BENEFIT
18 PLAN; EXCEPT THAT PRIOR AUTHORIZATION MUST NOT INCLUDE A STEP
19 THERAPY REQUIREMENT."

** ** ** ** **